Skip to content

Effect of Diffusion Optics Technology (DOT) Spectacle Lenses on Choroidal Thickness

Effect of Diffusion Optics Technology (DOT) Spectacle Lenses on Choroidal Thickness and Choroidal Vascularity Index in Emmetropes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05617794
Acronym
ASH-2
Enrollment
30
Registered
2022-11-15
Start date
2023-01-18
Completion date
2026-12-31
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile Myopia, Myopia, Myopia Progression

Brief summary

The objective of the study is to measure the effect of Diffusion Optics Technology (DOT) spectacle lenses on the choroidal thickness and choroidal vascularity index compared to control lenses.

Interventions

DEVICEDiffusion Optics Technology (DOT) Pattern Spectacle Lens

DOT Pattern Spectacle Lens

DEVICEControl Spectacle Lens

Control Spectacles

Sponsors

SightGlass Vision, Inc.
Lead SponsorINDUSTRY
University of Waterloo
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
8 Years to 14 Years
Healthy volunteers
Yes

Inclusion criteria

* Are 8-14 years of age; * Are able to read (or be read to), understand and sign the assent document; * Are accompanied by a parent or legal guardian who is able to read, understand and sign the parental information and permission document; * Are emmetropic by non-cycloplegic auto-refraction, which means both refractive meridians should be within +1.00D and -1.00D inclusively; * Are willing and able to follow instructions.

Exclusion criteria

* Are participating in any concurrent interventional clinical or research study; * Have a history of myopia control treatment in the past year; * Have amblyopia in either eye or known to have any other binocular vision disorder, such as accommodative insufficiency; * Have any known active ocular disease and/or infection; * Have a systemic condition that in the opinion of the investigator may affect a study outcome variable. Examples include diabetes mellitus, hyperthyroidism; * Are using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable. Examples include Atropine eye drops; * Have undergone strabismus surgery, refractive error surgery or intraocular surgery; * Are a child of a member of the study team.

Design outcomes

Primary

MeasureTime frameDescription
Choroidal Thickness30 minutes and 60 minutesChange from Baseline, 30 minutes and 60 minutes
Retinal and Choroidal Thickness30 minutes and 60 minutesChange from Baseline, 30 minutes and 60 minutes

Secondary

MeasureTime frameDescription
Software Method Comparison30 minutes and 60 minutesComparison of measurements using different software methods; manual, semiautomated and automated software

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026